Universal immunization of BC infants with four doses of conjugate pneumococcal vaccine was introduced in September 2003. There is already a dramatic decline in the rate of invasive pneumococcal disease in those under the age of 5. (Figure).
The immune response to conjugate vaccine is proving sufficiently robust—post-marketing studies now provide evidence that three doses will prove as immunogenic as four in healthy infants. On the basis of this evidence, BC’s Communicable Disease Policy Committee has advised that BC follow Quebec, Australia, and the United Kingdom and provide a three-dose schedule of conjugated pneumococcal vaccine beginning January 2007. The new schedule will include immunization at ages 2, 4, and 12 months. This is a change from the current schedule of 2, 4, 6, and 18 months.
All immunizing physicians and nurses should understand the rationale for this change.
Studies that examined use of two doses of conjugate pneumococcal vaccine in early infancy followed by a further dose closer to age 1 year (a total of three doses) indicated excellent induction of memory response as ascertained by high levels of antibodies. One of these studies made direct comparison with a four-dose series and found no disadvantage in immunogenicity for the three-dose series.[2-4]
The Northern California Kaiser Permanente trials determined the following outcomes:
• Efficacy of the vaccine was 97.4% for invasive disease caused by a vaccine serotype, for fully vaccinated (four doses) children.
• Effectiveness (intention to treat analysis) included all children who received at least one dose of the vaccine. Effectiveness was not significantly different from efficacy and was 93.9% (95% CI 79.6 to 98.5).
The US initiated a pneumococcal conjugate vaccine program in 2001. Vaccine shortages offered an opportunity for the Centers for Disease Control to conduct a case control study comparing the effectiveness of a three-dose series with a four-dose series. Preliminary results indicated that three doses of vaccine provided protection equivalent to four doses.
A simulation model in Quebec shows a reduction in morbidity of 77.8% for the 2-, 4-, and 12-month schedule, and 78.1% for the four-dose (2, 4, 6, and 18 months) schedule. The model also outlined the waste of continuing a four-dose rather than a three-dose schedule. Typically, in Canada there is support for health interventions that cost $25 000 to $50 000 per quality-adjusted life-year saved. A decision to retain four doses over three would at best cost $7.83 million per case prevented and $2 million per quality-adjusted life-year saved.
Parents and practitioners generally will welcome reduction in doses. The National Advisory Committee on Immunization statement on conjugate pneumococcal immunization permits a reduced dose schedule.
Invasive pneumococcal disease (IPD) is reportable by physicians and laboratories in BC. Surveillance will continue along with extra efforts to ensure that all available isolates from IPD cases are serotyped so that it can be determined if there is any increase in the rate of cases caused by vaccine-preventable strains among immunized children. A four-dose recommendation will be retained for children at higher risk for IPD (First Nations children and those with predisposing medical illness).
The current vaccine schedules are complex. This may be the first of several possible simplifications. The BC Communicable Disease Policy Committee is also examining the possibility of using hexavalent preparations to reduce the need for separate pentavalent and hepatitis B shots. A combined measles, mumps, rubella, and varicella vaccine will soon be available for evaluation and consideration. There will be ongoing efforts to ensure that we are as efficient as possible in providing protection from vaccine-preventable disease.
—David M. Patrick, MD,
—Cheryl McIntyre, RN
—Monika Naus, MD, MHSc
—Jastej Dhaliwal, MSc
—Marilyn McIvor, RN, MHA
—Danuta Skowronski, MD, MHSc
BC Centre for Disease Control
—Perry Kendall, MD
BC Ministry of Health Services
1. Paulus S, David ST, Tang W, et al. Incidence of invasive pneumococcal disease after introduction of the Universal Infant Immunization Program, British Columbia (2002-2005) CCDR 2006;32:14. Full Text
2. Esposito S, Pugni L, et al. Immunogenicity, safety, and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5, and 11 months post-natally to pre- and full-term infants. Vaccine 2005;23:1703-1708. PubMed Abstract Full Text
3. Goldblatt D, Suthern J, Ashton L, et al. Immunogenicity and boosting following a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Fourth International Symposium on Pneumococci and Pneumococcal Diseases, Helsinki, Finland, April 2006;25:312-319.
4. Kayhty H, Ahman H, Eriksson K, et al. Pneumococcal conjugate vaccine (PNCCRM) is immunogenic when administered at 3, 5, and 11 months of age. Pediatr Infect Dis J 2005;24:108-114.
5. Black S, Shinefield H, Fireman B, et al. Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-195. PubMed Abstract Full Text
6. CDC. Notice to readers: Limited supply of pneumococcal conjugate vaccine: Suspension of recommendation for fourth dose. MMWR 2004;53:108-109. Full Text
7. DeWals P, Erickson LJ, Farand L, et al. Assessment of the appropriateness of an immunization program for pneumococcal infections in children using a reduced number of doses of conjugate vaccine. January 2005. www.inspq.qc.ca (accessed 27 October 2006).
8. National Advisory Committee on Immunization. Update on the recommendations for the routine use of pneumococcal conjugate vaccine for infants. Canada Communicable Diseases Report 2006;32(ACS-4). www.phac-aspc.gc.ca/publicat/ccdr-rmtc/06vol32/acs-04/index.html (accessed 27 October 2006).
Above is the information needed to cite this article in your paper or presentation. The International Committee
of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally
accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
About the ICMJE and citation styles
The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.
An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.
BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:
- Only the first three authors are listed, followed by "et al."
- There is no period after the journal name.
- Page numbers are not abbreviated.
For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org